US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Apimeds Pharmaceuticals US, Inc.

News headline image
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Tickers APUS
News headline image
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
From Apimeds Pharmaceuticals US, Inc.
Via GlobeNewswire
Tickers APUS
News headline image
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Tickers APUS
News headline image
Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Tickers APUS
News headline image
Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Tickers APUS
News headline image
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Tickers APUS
News headline image
Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Tickers APUS
News headline image
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Tickers APUS
News headline image
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Tickers APUS
News headline image
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Tickers APUS
News headline image
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Tickers APUS
News headline image
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
From Apimeds Pharmaceuticals US, Inc.
Via GlobeNewswire
Tickers APUS
News headline image
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
From Apimeds Pharmaceuticals US, Inc.
Via GlobeNewswire